Avalanche boosts IPO as 2 more biotechs go public this week

Blindness drug developer Avalanche Biotechnologies Inc. boosted its IPO target to $93 million from $86 million, hoping to sell 6...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.